The Government is planning to provide weight loss drugs to unemployed people living with obesity. This new initiative aims to tackle the rising rates of obesity in the UK and may also help people return to work. However, there are serious side effects to be aware of.
Prime Minister Sir Keir Starmer stated that these drugs would be “very helpful” for those requiring weight loss. Health Secretary Wes Streeting mentioned that the program could also alleviate pressure on the NHS, which spends around £11 billion a year on obesity-related illnesses.
The proposed plan has sparked controversy, with some critics arguing that it punishes hard-working citizens and fails to promote an understanding of healthy diet choices. Andrew Pierce from GB News raised concerns about the long-term effects and financial implications of this scheme.
Data from the NHS shows that 29 percent of adults in England were classified as obese in 2022, and 64 percent were categorized as overweight. The Labour Government is introducing a five-year trial in Greater Manchester, testing the GLP-1 weight loss drug Mounjaro on 250,000 participants to see if it can effectively reduce obesity and joblessness.
The NHS currently offers two weight loss injections: Wegovy (semaglutide) and Saxenda (liraglutide), which require referrals to specialized weight management services.
Experts warn that GLP-1 drugs can cause several side effects, including:
- Nausea
- Vomiting
- Diarrhea
- Constipation
More serious potential side effects include inflammation of the pancreas, gallbladder disease, and kidney issues. Patients are advised to seek immediate medical assistance for severe abdominal pain, inability to pass gas, and jaundice.
For those considering these weight loss options, it’s crucial to weigh the potential benefits against the risks involved.
Source: Bristol Live
